Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

6.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types.

Nature communications·2025
Same author

Antitumor Immunity Mediated by Engineered Stem Cells Exploiting TRAIL-Induced Cell Death and FLT3L Immunomodulation.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Retraction Note: Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells.

Nature communications·2025
Same author

C12ORF57: a novel principal regulator of synaptic AMPA currents and excitatory neuronal homeostasis.

bioRxiv : the preprint server for biology·2025
Same author

A zwitterionic twist.

Nature reviews. Chemistry·2024
Same author

Editorial Expression of Concern: Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization.

Oncogene·2024

Related Experiment Video

Updated: Feb 22, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.8K

Repurposing Tumor Cells: A Paradigm Shift in Cell-Based Therapies for Cancer.

Kok-Siong Chen1,2, Laura Y Lin1,2, Yi-Ching Chen1,2

  • 1Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 20, 2026
PubMed
Summary

This study proposes repurposing tumor cells as therapeutic agents, not just targets. Engineered tumor cells can deliver treatments and enhance anti-cancer immunity, offering a novel cancer treatment strategy.

More Related Videos

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

10.3K
Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells
10:57

Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells

Published on: October 24, 2019

11.0K

Related Experiment Videos

Last Updated: Feb 22, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.8K
Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

10.3K
Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells
10:57

Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells

Published on: October 24, 2019

11.0K

Area of Science:

  • Oncology
  • Immunotherapy
  • Biotechnology

Background:

  • Conventional cancer therapies often cause collateral damage and immune suppression.
  • Tumor cells possess inherent properties like self-homing and antigen diversity that can be leveraged therapeutically.

Purpose of the Study:

  • To explore the paradigm-shifting concept of repurposing tumor cells as active therapeutic agents.
  • To analyze the limitations of early whole-cell vaccine approaches and propose next-generation strategies.
  • To examine the translational challenges and outline a clinical roadmap for tumor cell-based therapies.

Main Methods:

  • Critical analysis of mechanistic failures in early whole-cell vaccine approaches.
  • Discussion of next-generation strategies including "killer vaccines," APC-like reprogramming, and Trojan horse delivery of oncolytic viruses.
  • In-depth examination of translational challenges: safety engineering, manufacturing, regulatory, patient selection, and ethics, drawing parallels with CAR-T cell therapy.

Main Results:

  • Early whole-cell vaccines showed limited efficacy due to tumor resistance and immunosuppression.
  • Next-generation strategies aim to overcome these limitations by engineering tumor cells for therapeutic delivery and immune modulation.
  • Tumor cell-based therapies hold potential to remodel the tumor microenvironment and act as antigen-presenting cells.

Conclusions:

  • Repurposing tumor cells offers a novel therapeutic avenue, transforming tumors into catalysts for their own destruction.
  • Overcoming translational challenges is crucial for the clinical success of these therapies.
  • Tumor cell-based therapies could complement existing treatments like immune checkpoint inhibitors and adoptive cell therapies.